ClinicalTrials.gg
Not yet recruitingNCT07349329Updated Jan 16, 2026

A Study to Evaluate the Efficacy and Safty of 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA)

A Phase 3 interventional study of 608 and Placebo in Axial Spondyloarthritis, Non-Radiographic, sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-16.

Sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (part of 3SBio Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
380
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Non-Radiographic Axial Spondyloarthritis with a site in China — 6 open to participants now, 6 under way, 3 of them phase 3. Non-Radiographic Axial Spondyloarthritis · China.

Planned enrollment
2nd of 10
380 · median 227
Started
2026
with 2 others
Phase 3
6 of 11
2 open now
Registered
10th of 11
by date
Lead sponsor
2 of 11
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Among the 11 studies in Non-Radiographic Axial Spondyloarthritis with a site in China, this one is the 2nd largest by planned enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2026, is one of 6 in phase 3, and was the 10th registered.

Non-Radiographic Axial Spondyloarthritis

33 studies on the registry are indexed under Non-Radiographic Axial Spondyloarthritis; 12 are open to participants now.

Browse Non-Radiographic Axial Spondyloarthritis studies →

Open to participants now

6 of the 11 studies in Non-Radiographic Axial Spondyloarthritis with a site in China are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 5 Non-Radiographic Axial Spondyloarthritis studies recruiting now, 4 set no upper age limit and 1 stops at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Non-Radiographic Axial Spondyloarthritis with a site in China, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of 608 in patients with nr-axSpA.

Read the detailed description

The purpose of this study is to demonstrate the clinical efficacy, safety of 608 compared to placebo in patients with nr-axSpA.

03

Conditions studied

  • Axial Spondyloarthritis, Non-Radiographic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female and male patients at least 18 years of age at the time of screening.
  2. Diagnosis of axial spondyloarthritis according to Ankylosing Spondylo Arthritis International Society (ASAS) axial spondyloarthritis criteria
  3. Objective signs of inflammation (magnetic resonance imaging (MRI) or abnormal C-reactive protein)
  4. Total back pain as measured by NRS ≥ 4 at baseline

Exclusion criteria

Exclusion Criteria:

  1. Patients with other uncontrolled active inflammatory diseases.
  2. Clinical laboratory tests and other tests that reveal abnormalities with clinical significance
  3. Patients who have active , or infections as determined by positive results at Screening.
  4. History of cancer.
  5. Known or suspected history of .
  6. Known with allergic or intolerant to mometasone furoate spray or 608/placebo.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
380 participants (estimated)

Study arms

  • Experimental
    608

    608 subcutaneous (SC) injection.

    Drug: 608

  • Placebo comparator
    Placebo

    Placebo subcutaneous (SC) injection.

    Drug: Placebo

Interventions

  • Drug608

    608 subcutaneous (SC) injection.

  • DrugPlacebo

    Placebo subcutaneous (SC) injection.

06

What researchers measure

Primary outcomes

  1. 1. The Percentage of Participants Who Achieved an Assessment of Spondylo Arthritis International Society (ASAS) 40 Response

    Assessment of Spondylo Arthritis International Society criteria (ASAS) consist of 6 domains (4 main and 2 additional assessment domains): 1. Patient's global assessment measured on a NRS; 2. Patient's assessment of back pain, measured on a NRS; 3. Function represented by Bath Ankylosing Spondylitis Functional Index (BASFI) average of 10 questions as measured by NRS; 4. Inflammation represented by mean duration and severity of morning stiffness, on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) as measured by NRS; 5. Spinal mobility represented by the Bath Ankylosing Spondylitis Metrology Index (BASMI) lateral spinal flexion assessment; 6. C-reactive protein (acute phase reactant). ASAS40 response is defined as an improvement of ≥40% and ≥2 units on a scale of 10 in at least three of the four ASAS main domains and no worsening at all in the remaining domain. A higher score on the NRS signifies higher severity.

    Time frame: From Baseline to Week 16

Secondary outcomes

  1. 2. The Percentage of Participants Who Achieved an Assessment of Spondylo Arthritis International Society (ASAS) 20 Response

    Assessment of Spondylo Arthritis International Society criteria (ASAS) consist of 6 domains (4 main and 2 additional assessment domains): 1. Patient's global assessment measured on a NRS; 2. Patient's assessment of back pain, measured on a NRS; 3. Function represented by Bath Ankylosing Spondylitis Functional Index (BASFI) average of 10 questions as measured by NRS; 4. Inflammation represented by mean duration and severity of morning stiffness, on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) as measured by NRS; 5. Spinal mobility represented by the Bath Ankylosing Spondylitis Metrology Index (BASMI) lateral spinal flexion assessment; 6. C-reactive protein (acute phase reactant). ASAS 20 response is defined as an improvement of ≥20% and ≥1 unit on a scale of 10 in at least three of the four main domains and no worsening of ≥20% and ≥1 unit on a scale of 10 in the remaining domain. A higher score on the NRS signifies higher severity.

    Time frame: From Baseline to the Week 16

07

Study locations

1 site
  • Site 01
    Beijing, 100730, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2026; primary completion for Apr 2028, 25 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2026
First posted
Jan 16, 2026
StartEst.
Mar 9, 2026
Primary completionEst.
Apr 19, 2028
CompletionEst.
Feb 21, 2029
Last update
Jan 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07349329
Responsible party
Sponsor
First posted
Jan 16, 2026
Start date
Mar 9, 2026 (estimated)
Primary completion
Apr 19, 2028 (estimated)
Completion
Feb 21, 2029 (estimated)
Last update
Jan 16, 2026

Study contacts

Qinghong Zhou, BS
Contact
zhouqinghong@3sbio.com
18911301578
Qinghong Zhou, BS
study director · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Xiaofeng Zeng, MD
principal investigator · Peking Union Medical College Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion